Home › NDC Lookup › RxCUI directory › RxCUI 1052658

Etravirine 200 MG Oral Tablet — RxCUI 1052658

RxNorm drug concept · Semantic clinical drug
RxCUI 1052658 Semantic clinical drug · SCD ● Current RxNorm concept 16 FDA products 16 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1052658
Official nameEtravirine 200 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped16
Package NDCs mapped16
Reported Medicaid activity (SDUD)1,620 prescriptions · 16 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Etravirine: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Yes, it really does matter. Studies showed that taking etravirine on an empty stomach cuts the amount your body absorbs by about half. That's a significant drop that could make the...
  • Why do I have to take this with food — does it really matter?
  • A mild rash is actually fairly common with etravirine, especially in the first couple of weeks, and it often goes away on its own within one to two weeks. However, if the rash is s...
  • What should I do if I get a rash while taking etravirine?
📖 Read our full Etravirine guide →

🕸️ Concept Web — How Etravirine 200 MG Oral Tablet Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Etravirine 200 MG Oral Tablet RxCUI 1052658

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Etravirine 475969
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Intelence 758552
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Etravirine Oral Tablet 754760
    • Etravirine Oral Product 1163783
    • Etravirine Pill 1163784
    • Etravirine Oral Tablet [Intelence] 758554
    • Intelence Oral Product 1173436
    • Intelence Pill 1173437
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Etravirine 200 MG SCDC · 1052657
  • Etravirine Oral Tablet SCDF · 754760
  • Etravirine Oral Product SCDG · 1163783
  • Etravirine Pill SCDG · 1163784

Brand-Name Concepts

  • Etravirine 200 MG Oral Tablet [Intelence] SBD · 1052660
  • Etravirine 200 MG [Intelence] SBDC · 1052659
  • Etravirine Oral Tablet [Intelence] SBDF · 758554
  • Intelence Oral Product SBDG · 1173436
  • Intelence Pill SBDG · 1173437
  • Intelence BN · 758552

📦 FDA Products & Package NDCs

16 products · 16 package NDCs
16 package NDCs map to RxCUI 1052658 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
10147-0570-01 120 TABLET in 1 BOTTLE, PLASTIC (10147-0570-1) Etravirine Patriot Pharmaceuticals 2025-04-01
10147-0571-01 60 TABLET in 1 BOTTLE, PLASTIC (10147-0571-1) Etravirine Patriot Pharmaceuticals 2025-04-01
42291-0473-12 120 TABLET in 1 BOTTLE (42291-473-12) etravirine AvKARE 2022-10-04
42291-0474-60 60 TABLET in 1 BOTTLE (42291-474-60) etravirine AvKARE 2022-10-04
59676-0570-01 120 TABLET in 1 BOTTLE, PLASTIC (59676-570-01) Intelence Janssen Products LP 2008-01-18
59676-0571-01 60 TABLET in 1 BOTTLE, PLASTIC (59676-571-01) Intelence Janssen Products LP 2010-12-22
59676-0572-01 120 TABLET in 1 BOTTLE, PLASTIC (59676-572-01) Intelence Janssen Products LP 2012-03-26
60219-1720-07 120 TABLET in 1 BOTTLE, PLASTIC (60219-1720-7) etravirine Amneal Pharmaceuticals NY LLC 2021-06-14
60219-1721-07 120 TABLET in 1 BOTTLE, PLASTIC (60219-1721-7) etravirine Amneal Pharmaceuticals NY LLC 2021-06-14
60219-1722-06 60 TABLET in 1 BOTTLE, PLASTIC (60219-1722-6) etravirine Amneal Pharmaceuticals NY LLC 2021-06-14
69315-0285-20 120 TABLET in 1 BOTTLE (69315-285-20) ETRAVIRINE Leading Pharma, LLC 2022-06-05
69315-0286-06 60 TABLET in 1 BOTTLE (69315-286-06) ETRAVIRINE Leading Pharma, LLC 2022-06-05
69452-0254-22 120 TABLET in 1 BOTTLE, PLASTIC (69452-254-22) etravirine Bionpharma Inc. 2026-01-01
69452-0255-17 60 TABLET in 1 BOTTLE, PLASTIC (69452-255-17) etravirine Bionpharma Inc. 2026-01-01
80005-0112-12 120 TABLET in 1 BOTTLE (80005-112-12) ETRAVIRINE Carnegie Pharmaceuticals LLC 2022-06-07
80005-0113-09 60 TABLET in 1 BOTTLE (80005-113-09) ETRAVIRINE Carnegie Pharmaceuticals LLC 2022-06-07
Observed labelers: Amneal Pharmaceuticals NY LLC (3) · Janssen Products LP (3) · AvKARE (2) · Bionpharma Inc. (2) · Carnegie Pharmaceuticals LLC (2) · Leading Pharma, LLC (2) · +1 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.